Epinephrine Market Analysis | CMI (1)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
EPINEPHRINE MARKET ANALYSIS

• Epinephrine Market - Global Forecast to 2026, by
  Product Type (Auto-injector, Prefilled Syringes,
  and Ampoules and Vials), by Application
  (Anaphylaxis, Cardiac Arrest, Superficial
  Bleeding, Respiratory Disorders and Others), by
  Distribution Channel (Hospital Pharmacies, Retail
  Pharmacies, and Online Pharmacies) and by Region
  (North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa) - Size, Share,
  Outlook, and Opportunity Analysis, 2018-2026
• The global epinephrine market size was valued at
  US 2,040 million in 2017, and is expected to
  exhibit a CAGR of 11.0 over the forecast period
  (2018 2026).

3
Figure 1. Global Epinephrine Market Value (US
Mn), by Region, 2017
4
Market Drivers

• Increasing support from government and insurance
  agencies for generic products to propel
  Epinephrine Market growth
• Launch of cost effective generic epinephrine
  products by the manufacturers is majorly
  attributed to the high price of EpiPen developed
  by Mylan NV. The price hike was not accepted by
  the public, as the drug price increased to more
  than 400 over a decade.
• According to data provided by Elsevier Clinical
  Solutions Gold Standard Drug Database, 2016, the
  cost of EpiPen was US 103.50 in 2009, where the
  price increased up to US 264.50 in 2013. The
  price of the product further increased by 75
  costing around US 461 in 2015, whereas the price
  reached to US 608.61 in 2016.

5

• Furthermore, support of regulatory agencies is
  expected to streamline the approval of generic
  copies of drugs, thus allowing the launch of drug
  substitutes without affecting the clinical effect
  or safety profile. For instance, in October 2017,
  the commissioner of FDA announced plans to
  accelerate development of generic versions that
  combine a drug and a device. In November 2017,
  the FDA issued guidance for developing generic
  copies of complex medicines such as EpiPen to
  reach the market, without affecting safety and
  efficacy, thereby providing a lower-cost option
  and to meet the demand of drug shortages.
• Also, insurance companies and state Medicaid
  programs have stopped covering branded products
  such as EpiPens, thereby favoring the adoption
  for alternative epinephrine auto-injectors, as
  the high cost of the products are directly
  shifted onto the payers. For instance, in 2017,
  the private insurer Cigna Corp. changed the
  policies for providing easy access of generic
  auto-injectors to patients, as the insurer will
  cover Mylan's US 300 generic version of the
  EpiPen, which is cost-effective alternative as
  compared to the branded drug.

6
Market Restraints

• However, unavailability of approved drugs due to
  increasing number of product recalls by various
  developers is a factor hindering growth of the
  global epinephrine market. For instance, in 2015,
  Sanofi US voluntarily recalled Auvi-Q
  (epinephrine injection, USP) on the market
  including both 0.15 mg and 0.3 mg strengths for
  hospitals, retailers and consumers, as the
  products had inaccurate dosage delivery, thus
  included failure to provide intended drug dose.

7
Figure 2. Global Epinephrine Market Share (), by
Product Type, 2018 and 2026
8
Market Opportunities

• Increase in prevalence of chronic respiratory
  diseases to bolster the market growth
• Epinephrine is available in different doses and
  concentrations for delivery by different routes
  and for different indications, including
  respiratory disorders. According to the World
  Health Organization (WHO), 2018, Chronic
  Respiratory Diseases (CRDs) affect more than 1
  billion people worldwide and asthma is a large
  contributor, affecting children, adults, and
  elderly population often throughout their entire
  lives. The WHO in 2017, stated that over 300
  million patients suffered from asthma in 2013,
  and are expected to increase to over 400 million
  by 2025 globally.
• North America dominates the global epinephrine
  market, owing to increasing number of patients
  suffering from respiratory disease such as
  asthma. For instance, according to the Asthma and
  Allergy Foundation of America, 2014, anaphylaxis
  is a severe life-threatening allergic reactions
  occurring at least 1 in every 50 people in the
  U.S., and its rate is as high as 1 in every 20
  people.
• Also, various players in the region are involved
  in developing innovative products, which in turn
  is expected to augment market growth. For
  instance, in July 2016, MannKind Corporation
  initiated developmental process for single-use
  disposable epinephrine inhaler, thereby providing
  an affordable and needle-free alternative.

9
Key Players

• Major players operating in the global epinephrine
  market include Mylan N.V., Pfizer, Inc., Teva
  Pharmaceuticals Industries Ltd., Impax
  Laboratories, Inc., Kaleo, Inc., Adamis
  Pharmaceuticals Corporation, Bausch Health
  Companies, and ALK- Abello A/S.

10
Key Development

• Market players are focused on launching cost
  effective versions for patients suffering from
  severe allergies, requiring constant access to
  life-saving epinephrine, thereby providing
  affordable options and propelling the market
  growth.
• For instance, in August 2018, Teva
  Pharmaceuticals received the Food and Drug
  Administration (FDA) approval for first generic
  versions of EpiPen and EpiPen Jr, for the
  emergency treatment of allergic reactions,
  including life-threatening allergies
  (anaphylaxis), in adults and pediatric patients
  weighing more than 33 pounds.

11

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/epinephrine-market-2401

12
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

14

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/